1. "Thoracic Oncology"
Formats
  1. Meeting Abstract (1449)
  2. Journal Article (1218)
  3. Review (57)
  4. Editorial (37)
  5. Book Section (35)
  6. Conference Paper (20)
  7. Guidelines (18)
  8. Correspondence (5)
  9. Research Letter (5)
  10. Miscellaneous (4)
  11. Book Whole (2)
Groups
  1. Department of Medicine (2850)
  2. Solid Tumor Oncology Division (2850)
  3. Thoracic Oncology (2850)
  4. GSK Faculty (904)
  5. Human Oncology and Pathogenesis Program (528)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (496)

More Groups

People
  1. Mark Kris (830)
  2. Gregory Riely (552)
  3. Alexander Drilon (505)
  4. Charles Rudin (406)
  5. Matthew Hellmann (397)
  6. Marc Ladanyi (373)

More People

Years
  1. 2023 (119)
  2. 2022 (336)
  3. 2021 (337)
  4. 2020 (257)
  5. 2019 (259)
  6. 2018 (251)

More Years

Publications
  1. Journal of Clinical Oncology (586)
  2. Journal of Thoracic Oncology (429)
  3. Annals of Oncology (230)
  4. Clinical Cancer Research (143)
  5. Cancer Research (125)
  6. International Journal of Radiation Oncology, Biology, Physics (74)

More Publications

Publishers
  1. American Society of Clinical Oncology (643)
  2. Elsevier Inc. (615)
  3. American Association for Cancer Research (349)
  4. Oxford University Press (283)
  5. Nature Publishing Group (123)
  6. Elsevier Science, Inc. (68)

More Publishers

Results (2850)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Predictors of benefit to radiation for oligoprogressive disease in EGFR -mutant metastatic non-small cell lung cancer patients treated with osimertinib
    Meeting Abstract

    Chen, M. F.; Ma, J.; Kris, M. G.; Gomez, D. R.; Yu, H. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Patient characteristics, treatment patterns, and clinical outcomes among patients with de novo advanced or metastatic (stage IIIB–IV) non-small cell lung cancer in a real-world setting
    Meeting Abstract

    Yang, M.; MacEwan, J. P.; Sriteja Boppudi, S.; McClain, M.; O'Hara, R.; Paik, P. K.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical outcomes and genomic landscape of patients (pts) with EGFR-mutant lung cancer (EGFR+ LC) with central nervous system (CNS) metastases (mets)
    Meeting Abstract

    Sui, J. S. Y.; Wilcox, J.; Tischfield, S.; Choudhury, N. J.; Riely, G. J.; Kris, M. G.; Boire, A. A.; Yu, H. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Large-scale clinicogenomic models of solid tumor CNS metastasis
    Meeting Abstract

    Jee, J.; Luthra, A.; Fong, C.; Pichotta, K.; Tran, T.; Altoe, M.; Miller, A.; Shen, R.; Berger, M. F.; Sanchez-Vega, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Quantifying the growth of clinical actionability in precision oncology using OncoKB
    Meeting Abstract

    Suehnholz, S. P.; Kundra, R.; Nandakumar, S.; Nissan, M. H.; Zhang, H.; Lu, C.; Dhaneshwar, A.; Fernandez, N.; Carrero, S.; Arcila, M. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Association of smoking history extracted from electronic health records (EHR) using machine-learning methods and tumor characteristics in patients with lung cancer
    Meeting Abstract

    Mukherjee, S.; Schroeder, A.; Chatterjee, S.; Cadley, J.; Falcon, C. J.; Mehine, M.; Bandlamudi, C.; Chatterjee, A.; Ladanyi, M.; Solit, D. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Global adoption of remote technologies to enable patient-centric oncology clinical trials: Analysis by the Bloomberg New Economy International Cancer Coalition
    Meeting Abstract

    Daly, R. M.; Brawley, O. W.; Gospodarowicz, M. K.; Olopade, O. I.; Fashoyin, I.; Wolodzko Smart, V.; Chang, I. F.; Tendler, C. L.; Kim, G.; Fuchs, C. S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Patient characteristics, treatment patterns, and factors of biomarker testing among patients with advanced non-small cell lung cancer (ANSCLC) in the US, 2012-2020
    Meeting Abstract

    Yang, M.; MacEwan, J. P.; Honnold, R.; McClain, M. R.; O'Hara, R.; Liu, F.; Paik, P.
    Value in Health (2023)

    Fulltext@MSK | Save
  • KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC
    Meeting Abstract

    Wakelee, H. A.; Liberman, M.; Kato, T.; Tsuboi, M.; Lee, S. H.; He, J.; Gao, S.; Chen, K. N.; Dooms, C. A.; Majem, M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study
    Meeting Abstract

    Yang, J. C. H.; Lee, D. H.; Lee, J. S.; Fan, Y.; de Marinis, F.; Okamoto, I.; Inoue, T.; Cid, J. R. R.; Zhang, L.; Yang, C. T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save